2021
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas
Yeung J, Yaghoobi V, Miyagishima D, Vesely MD, Zhang T, Badri T, Nassar A, Han X, Sanmamed MF, Youngblood M, Peyre M, Kalamarides M, Rimm DL, Gunel M, Chen L. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro-Oncology 2021, 23: 1922-1935. PMID: 33914067, PMCID: PMC8563319, DOI: 10.1093/neuonc/noab075.Peer-Reviewed Original ResearchConceptsColony-stimulating factor-1Myeloid cellsMalignant meningiomasTumor microenvironmentCSF1/CSF1RRNA-seqRNA sequencingHuman meningiomasImmune subsetsGene expressionT cellsTreatment strategiesNormalization cancer immunotherapyImportant regulatorCell typesNovel immunocompetent murine modelDeath ligand 1 (PD-L1) expressionCell death receptor-1Immunosuppressive myeloid cellsDeath receptor-1Ligand 1 expressionFactor 1Immune cell typesImmunocompetent murine modelEffective treatment strategies
2020
In Silico Analysis of the Immunological Landscape of Pituitary Adenomas
Yeung J, Vesely M, Miyagishima D. In Silico Analysis of the Immunological Landscape of Pituitary Adenomas. Neurosurgery 2020, 67 DOI: 10.1093/neuros/nyaa447_813.Peer-Reviewed Original ResearchIn Silico Analysis of Changes in Immunological Landscape During Malignant Transformation of IDH-mutant Low-grade Gliomas
Yeung J, Vesely M, Antonios J, Miyagishima D. In Silico Analysis of Changes in Immunological Landscape During Malignant Transformation of IDH-mutant Low-grade Gliomas. Neurosurgery 2020, 67 DOI: 10.1093/neuros/nyaa447_835.Peer-Reviewed Original ResearchClinical and economic burden of neurofibromatosis type 2 in the United States
Koo AB, Yeung JT, Freedman IG, Lee JH, Ahmed OM, Ma AK, Miyagishima DF, DiLuna M, Kahle K. Clinical and economic burden of neurofibromatosis type 2 in the United States. Clinical Neurology And Neurosurgery 2020, 197: 106053. PMID: 32683193, DOI: 10.1016/j.clineuro.2020.106053.Peer-Reviewed Original ResearchConceptsOpen resectionPatient demographicsRisk factorsMeningioma resectionMulti-year cross-sectional studyNeurofibromatosis type 2 (NF2) patientsSpine tumor resectionCommon admission diagnosesNational Inpatient SampleType 2 patientsCross-sectional studySignificant independent associationNeurofibromatosis type 2Regression analysisInflation-adjusted costAdmission diagnosisHospital stayDischarge weightIndependent predictorsObstructive hydrocephalusSurgical interventionDiagnosis codesHospital characteristicsInpatient populationInpatient SampleIn silico analysis of the immunological landscape of pituitary adenomas
Yeung JT, Vesely MD, Miyagishima DF. In silico analysis of the immunological landscape of pituitary adenomas. Journal Of Neuro-Oncology 2020, 147: 595-598. PMID: 32236778, PMCID: PMC7261241, DOI: 10.1007/s11060-020-03476-x.Peer-Reviewed Original ResearchConceptsPituitary adenomasImmunological landscapeImmune cellsM2 macrophagesPituitary tumorsAdenoma subtypesSilent pituitary tumorsMemory T cellsImmune cell typesDifferent immunotherapiesHigh CD8Immune infiltratesImmune landscapeSilent tumorsGH tumorsImmunological compositionMacrophage fractionT cellsMast cellsTumor subtypesSolid tumorsSubclinical casesAdenomasTumorsSubtypesTumor Location and Treatment Modality are Associated with Overall Survival in Adult Medulloblastoma
K A, Freedman I, Lee JH, Miyagishima D, Ahmed O, Yeung J. Tumor Location and Treatment Modality are Associated with Overall Survival in Adult Medulloblastoma. Cureus 2020, 12: e7061. PMID: 32226663, PMCID: PMC7089624, DOI: 10.7759/cureus.7061.Peer-Reviewed Original ResearchTumor locationOverall survivalAdult medulloblastomaPrognostic factorsAdult casesTreatment modalitiesSurvival timeMultivariate Cox proportional hazards modelWorse median survival timeCox proportional hazards modelOverall median survivalSignificant prognostic factorsBetter overall survivalEnd Results registryMedian survival timeMultivariate survival analysisUnited States SurveillanceProportional hazards modelCourse of treatmentAggressive brain tumorYears of ageMedian survivalSEER registryShorter survivalClinical variables